Slow-Release Oral Morphine for the Treatment of Opioid Use Disorder (pRESTO)
Repurposing Slow-Release Oral Morphine as a New Oral Alternative for the Treatment of Opioid Use Disorder
Sponsor: Canadian Institutes of Health Research (CIHR)
Terminated
Study unable to proceed per protocol due to COVID-19 precautions
Other terminated trials from Canadian Institutes of Health Research (CIHR)
- Copd · Phase PHASE2/PHASE3 · Feb 2026
- Insomnia · Phase NA · Dec 2024
- X Linked Myotubular Myopathy · Phase PHASE1/PHASE2 · May 2024
- Autism Spectrum Disorder · Phase NA · May 2023
- Age-related Macular Degeneration · Phase NA · Mar 2023
See all terminations from Canadian Institutes of Health Research (CIHR)
Other Fentanyl trials with similar outcome
Listed as NCT03948464, this PHASE3 trial focuses on Fentanyl and Methadone and remains terminated or withdrawn. Sponsored by Canadian Institutes of Health Research (CIHR), it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE3
Status: Suspended → Terminated
-
Jan 2021 — Mar 2022 [monthly]
Suspended PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Suspended PHASE3
▶ Show 2 earlier versions
-
Aug 2020 — Oct 2020 [monthly]
Suspended PHASE3
Status: Not Yet Recruiting → Suspended
-
Jun 2019 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Canadian Institutes of Health Research (CIHR)
- M. Eugenia Socias
- Mayne Pharma International Pty Ltd
- Vancouver Foundation
For direct contact, visit the study record on ClinicalTrials.gov .